title: The role of EMMPRIN expression in ovarian epithelial carcinomas.
abstract: OBJECTIVE
  Extracellular matrix metalloproteinase inducer (EMMPRIN) was reported to involve in the invasion and metastasis of malignancies by regulating the expression of vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs) in stromal and cancer cells. The study aimed to clarify the role of EMMPRIN expression in tumorigenesis and progression of ovarian epithelial carcinomas.
  
  
  METHODS
  EMMPRIN siRNA were transfected into ovarian carcinoma cells with the phenotypes and their related molecules examined. EMMPRIN expression was determined in ovarian normal tissue, benign and borderline tumors, and epithelial carcinomas by real-time PCR, western blot, and immunohistochemistry.
  
  
  RESULTS
  EMMPRIN siRNA treatment resulted in a lower growth, G 1 arrest, apoptotic induction, decreased migration, and invasion. The transfectants showed reduced expression of Wnt5a, Akt, p70s6k, Bcl-xL, survivin, VEGF, and MMP-9 than mock and control cells at both mRNA and protein levels. According to real-time PCR and western blot, EMMPRIN mRNA or protein level was higher in ovarian borderline tumor and carcinoma than normal ovary and benign tumors (P<0.05), and positively correlated with dedifferentiation and FIGO staging (P<0.05). Immunohistochemically, EMMPRIN expression was positively correlated with FIGO staging, dedifferentiation, Ki-67 expression, the lower cumulative and relapse-free survival rate (P<0.05).
  
  
  CONCLUSIONS
  Upregulated expression of EMMPRIN protein and mRNA might be involved in the pathogenesis, differentiation, and progression of ovarian carcinomas, possibly by modulating cellular events, such as proliferation, cell cycle, apoptosis, migration, and invasion.
authors: Department of Gynecology; The First Affiliated Hospital of China Medical University; Shenyang, China.
authors: Yang
authors: Y
authors: Zhao
authors: Shuo
authors: S
authors: Chen
authors: Wen-feng
authors: WF
authors: Gou
authors: Zhe-feng
authors: ZF
authors: Niu
authors: Shuang
authors: S
authors: Zhao
authors: Li-jun
authors: LJ
authors: Xiao
authors: Yasuo
authors: Y
authors: Takano
authors: Hua-chuan
authors: HC
authors: Zheng
mesh_terms: D000368:Aged; D051926:Basigin / Q000235:genetics* / Q000378:metabolism; D063646:Carcinogenesis / Q000235:genetics / Q000473:pathology; D000077216:Carcinoma, Ovarian Epithelial; D045744:Cell Line, Tumor; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D055785:Gene Knockdown Techniques; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D015999:Multivariate Analysis; D009375:Neoplasms, Glandular and Epithelial / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D010051:Ovarian Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D010641:Phenotype; D011379:Prognosis; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism
chemical_list: C497886:BSG protein, human; D012333:RNA, Messenger; D051926:Basigin
keywords: EMMPRIN; carcinogenesis; cellular phenotypes; ovarian cancer; prognosis; progression
references: Oncology. 2007;72(3-4):197-204
references: 18160808
references: Clin Exp Metastasis. 2003;20(7):621-31
references: 14669793
references: J Surg Res. 2010 May 15;160(2):260-7
references: 19286191
references: Cancer. 2004 Nov 1;101(9):1994-2000
references: 15372476
references: Anticancer Res. 2006 Sep-Oct;26(5A):3579-83
references: 17094486
references: Int J Cancer. 2006 Oct 15;119(8):1800-10
references: 16721788
references: Eur J Biochem. 2000 Jul;267(14):4372-80
references: 10880960
references: J Exp Clin Cancer Res. 2010 Jun 03;29:61
references: 20525232
references: Oncotarget. 2012 Apr;3(4):435-49
references: 22564965
references: Pathol Int. 2006 Jul;56(7):359-67
references: 16792544
references: Cell Cycle. 2011 Nov 15;10(22):3834-40
references: 22071625
references: Cell Mol Life Sci. 2008 Sep;65(18):2933-42
references: 18695939
references: World J Gastroenterol. 2005 Mar 14;11(10):1445-51
references: 15770719
references: Oncotarget. 2012 Nov;3(11):1439-54
references: 23183822
references: Anticancer Res. 2008 Jul-Aug;28(4B):2049-54
references: 18751374
references: Am J Pathol. 2005 Jan;166(1):209-19
references: 15632013
references: World J Gastroenterol. 2003 Jul;9(7):1415-20
references: 12854132
references: Pathol Oncol Res. 2009 Sep;15(3):369-74
references: 19048397
references: J Reprod Med. 2005 Jun;50(6):399-406
references: 16050564
references: Cancer Res. 2005 Apr 15;65(8):3193-9
references: 15833850
references: Cell Cycle. 2012 Aug 1;11(15):2793-8
references: 22801544
references: Clin Transl Oncol. 2012 Mar;14(3):190-6
references: 22374422
references: Trends Cell Biol. 2010 Jun;20(6):346-54
references: 20359892
references: Arch Histol Cytol. 2007 Dec;70(5):267-77
references: 18431027
references: Biochimie. 2005 Mar-Apr;87(3-4):361-8
references: 15781323
references: Int J Cancer. 2006 Jun 15;118(12):2991-8
references: 16425263
references: Pathol Oncol Res. 2011 Sep;17(3):705-11
references: 21448785
references: Oncogene. 2011 Oct 27;30(43):4410-27
references: 21532623
references: J Biol Chem. 2006 Apr 7;281(14):9719-27
references: 16443928
references: Mol Biol Cell. 2004 Sep;15(9):4043-50
references: 15201341
references: Oncotarget. 2011 Jun;2(6):477-84
references: 21646684
references: Cancer Invest. 2009 Mar;27(3):329-33
references: 19160100
references: Cell Death Differ. 2012 Nov;19(11):1779-90
references: 22595757
references: Br J Cancer. 2006 Nov 20;95(10):1371-8
references: 17088917
references: Am J Pathol. 2013 Feb;182(2):577-85
references: 23178078
references: Cell Biol Int. 2009 Feb;33(2):199-206
references: 19059491
references: Cell Cycle. 2013 Mar 15;12(6):972-86
references: 23442798
references: Oncogene. 2010 Jul 22;29(29):4145-56
references: 20514014
references: Transl Res. 2008 Sep;152(3):143-9
references: 18774544
references: Eur J Cancer Prev. 2007 Jun;16(3):196-202
references: 17415090
references: Oncol Rep. 2012 Jun;27(6):2003-9
references: 22427101
references: Cancer Res. 2001 Mar 1;61(5):2276-81
references: 11280798
references: Mol Cancer Res. 2004 Feb;2(2):73-80
references: 14985463
references: Mod Pathol. 2004 Sep;17(9):1141-9
references: 15167936
references: Cancer Res. 2004 Feb 15;64(4):1229-32
references: 14983875
references: Hum Cell. 2005 Mar;18(1):1-16
references: 16130895
references: J Cancer Res Clin Oncol. 2011 Apr;137(4):585-96
references: 20514493
references: Cancer Lett. 2006 Jun 18;237(2):289-97
references: 16046057
references: Histochem Cell Biol. 2008 Dec;130(6):1091-103
references: 18987874
references: Neoplasma. 2011;58(5):449-54
references: 21745000
references: Adv Exp Med Biol. 2008;622:79-87
references: 18546620
references: Med Oncol. 2011 Dec;28(4):1363-72
references: 20509007
references: Curr Top Dev Biol. 2003;54:371-89
references: 12696756
references: Front Biosci. 2008 May 01;13:5571-9
references: 18508606
references: Oncol Rep. 2011 Feb;25(2):425-32
references: 21165561